Risk factors for progressing to critical illness in patients with hospital-acquired COVID-19
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Risk factors for progression to critical illness in hospital-acquired coronavirus disease 2019 (COVID-19) remain unknown. Here, we assessed the incidence and risk factors for progression to critical illness and determined their effects on clinical outcomes in patients with hospital-acquired COVID-19. Methods: This retrospective cohort study analyzed patients admitted to the tertiary hospital between January 2020 and June 2022 with confirmed hospital-acquired COVID-19. The primary outcome was the progression to critical illness of hospital- acquired COVID-19. Patients were stratified into high-, intermediate-, or low-risk groups by the number of risk factors for progression to critical illness. Results: In total, 204 patients were included and 37 (18.1%) progressed to critical illness. In the multivariable logistic analysis, patients with preexisting respiratory disease (OR, 3.90; 95% CI, 1.04–15.18), preexisting cardiovascular disease (OR, 3.49; 95% CI, 1.11–11.27), immunocompromised status (OR, 3.18; 95% CI, 1.11–9.16), higher sequential organ failure assessment (SOFA) score (OR, 1.56; 95% CI, 1.28–1.96), and higher clinical frailty scale (OR, 2.49; 95% CI, 1.62–4.13) showed significantly increased risk of progression to critical illness. As the risk of the groups increased, patients were significantly more likely to progress to critical illness and had higher 28-day mortality. Conclusions: Among patients with hospital-acquired COVID-19, preexisting respiratory disease, preexisting cardiovascular disease, immunocompromised status, and higher clinical frailty scale and SOFA scores at baseline were risk factors for progression to critical illness. Patients with these risk factors must be prioritized and appropriately isolated or treated in a timely manner, especially in pandemic settings.
Abstract
Background/Aims: Risk factors for progression to critical illness in hospital-acquired coronavirus disease 2019 (COVID-19) remain unknown. Here, we assessed the incidence and risk factors for progression to critical illness and determined their effects on clinical outcomes in patients with hospital-acquired COVID-19. Methods: This retrospective cohort study analyzed patients admitted to the tertiary hospital between January 2020 and June 2022 with confirmed hospital-acquired COVID-19. The primary outcome was the progression to critical illness of hospital- acquired COVID-19. Patients were stratified into high-, intermediate-, or low-risk groups by the number of risk factors for progression to critical illness. Results: In total, 204 patients were included and 37 (18.1%) progressed to critical illness. In the multivariable logistic analysis, patients with preexisting respiratory disease (OR, 3.90; 95% CI, 1.04–15.18), preexisting cardiovascular disease (OR, 3.49; 95% CI, 1.11–11.27), immunocompromised status (OR, 3.18; 95% CI, 1.11–9.16), higher sequential organ failure assessment (SOFA) score (OR, 1.56; 95% CI, 1.28–1.96), and higher clinical frailty scale (OR, 2.49; 95% CI, 1.62–4.13) showed significantly increased risk of progression to critical illness. As the risk of the groups increased, patients were significantly more likely to progress to critical illness and had higher 28-day mortality. Conclusions: Among patients with hospital-acquired COVID-19, preexisting respiratory disease, preexisting cardiovascular disease, immunocompromised status, and higher clinical frailty scale and SOFA scores at baseline were risk factors for progression to critical illness. Patients with these risk factors must be prioritized and appropriately isolated or treated in a timely manner, especially in pandemic settings.
참고문헌 (40)
- Henry DA, "Effectiveness of COVID-19 vaccines : findings from real world studies", Med J Aust, 215, pp.149~151 (2021)
- "Therapeutics and COVID-19: living guideline" (2023)[URL]
- Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
- Petrilli CM, "Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City : prospective cohort study", BMJ, 369, pp.m1966~ (2020)
- Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
- Rosenthal N, "Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19", JAMA Netw Open, 3, pp.e2029058~ (2020)
- Mikami T, "Risk factors for mortality in patients with COVID-19 in New York City", J Gen Intern Med, 36, pp.17~26 (2021)
- Goodacre S, "Derivation and validation of a clinical severity score for acutely ill adults with suspected COVID-19 : the PRIEST observational cohort study", PLoS One, 16, pp.e0245840~ (2021)
- Knight SR, "Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol : development and validation of the 4C Mortality Score", BMJ, 370, pp.m3339~ (2020)
- Wu S, "Environmental contamination by SARS-CoV-2 in a designated hospital for coronavirus disease 2019", Am J Infect Control, 48, pp.910~914 (2020)
- "Bridging the gap between ethics and decision-making in pandemics: report of the WHO Pandemic Ethics and Policy Summit" (2021)[URL]
- Wu Y, "Incubation period of COVID-19 caused by unique SARS-CoV-2 strains : a systematic review and meta-analysis", JAMA Netw Open, 5, pp.e2228008~ (2022)
- Rubin LG, "2013 IDSA clinical practice guideline for vaccination of the immunocompromised host", Clin Infect Dis, 58, pp.309~318 (2014)
- Azoulay E, "Diagnosis of severe respiratory infections in immunocompromised patients", Intensive Care Med, 46, pp.298~314 (2020)
- Ramirez JA, "Treatment of community-acquired pneumonia in immunocompromised adults : a consensus statement regarding initial strategies", Chest, 158, pp.1896~1911 (2020)
- Rockwood K, "A global clinical measure of fitness and frailty in elderly people", CMAJ, 173, pp.489~495 (2005)
- "People who are immunocompromised" (2023)[URL]
- ARDS Definition Task Force, "Acute respiratory distress syndrome : the Berlin Definition", JAMA, 307, pp.2526~2533 (2012)
- Singer M, "The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)", JAMA, 315, pp.801~810 (2016)
- Chowdhury MZI, "Variable selection strategies and its importance in clinical prediction modelling", Fam Med Community Health, 8, pp.e000262~ (2020)
- Liu Y, "Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19", J Infect, 81, pp.e6~e12 (2020)
- Ji W, "Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea : a nationwide case-control study", J Korean Med Sci, 35, pp.e237~ (2020)
- Na YS, "In-hospital mortality prediction using frailty scale and severity score in elderly patients with severe COVID-19", Acute Crit Care, 37, pp.303~311 (2022)
- Dickson RP, "The role of the microbiome in exacerbations of chronic lung diseases", Lancet, 384, pp.691~702 (2014)
- Zhang S, "COVID‑19 and ischemic stroke : Mechanisms of hypercoagulability(Review)", Int J Mol Med, 47, pp.21~ (2021)
- Lee HY, "Preexisting clinical frailty is associated with worse clinical outcomes in patients with sepsis", Crit Care Med, 50, pp.780~790 (2022)
- Pansarasa O, "Altered immune system in frailty : genetics and diet may influence inflammation", Ageing Res Rev, 54, pp.100935~ (2019)
- Sablerolles RSG, "Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19(COMET) : an international, multicentre, retrospective, observational cohort study", Lancet Healthy Longev, 2, pp.e163~e170 (2021)
- Gottlieb RL, "Early remdesivir to prevent progression to severe Covid-19 in outpatients", N Engl J Med, 386, pp.305~315 (2022)
- Hammond J, "Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19", N Engl J Med, 386, pp.1397~1408 (2022)
- Beigel JH, "Remdesivir for the treatment of Covid-19-final report", N Engl J Med, 383, pp.1813~1826 (2020)
- Geetha S, "Fuzzy case-based reasoning approach for finding COVID-19patients priority in hospitals at source shortage period", Expert Syst Appl, 178, pp.114997~ (2021)
- Cho SY, "MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea : an epidemiological outbreak study", Lancet, 388, pp.994~1001 (2016)
- Gondi S, "Personal protective equipment needs in the USA during the COVID-19 pandemic", Lancet, 395, pp.e90~e91 (2020)
- Adams K, "Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States : living test negative design study", BMJ, 379, pp.e072065~ (2022)
- Esper FP, "Alpha to Omicron : disease severity and clinical outcomes of major SARS-CoV-2 variants", J Infect Dis, 227, pp.344~352 (2023)
- Benowitz NL, "Tobacco product use and the risks of SARS-CoV-2 infection and COVID-19 : current understanding and recommendations for future research", Lancet Respir Med, 10, pp.900~915 (2022)
- Hwang SD, "The status of genomic surveillance of the Coronavirus disease 2019 virus variants in Chungcheong region in 2021-2022", Public Health Wkly Rep, 16, pp.1257~1271 (2023)
- "COVID-19domestic cases and vaccination status in the country: press release" (2022)[URL]